J. Aucoin

OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

H. Groen, L. Urban, E. Felip, 2019, Journal of Thoracic Oncology.

Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer’s disease

L. Descarries, X. Tong, E. Hamel, 2005, Neuroscience.

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

L. Urban, E. Felip, Han Chang, 2023, Journal for ImmunoTherapy of Cancer.

Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of Advanced NSCLC: Overall Survival Analysis of Checkmate 817

L. Urban, E. Felip, L. Paz-Ares, 2019 .

Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.

J. Ajani, Y. Janjigian, F. Franke, 2017 .

CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.

J. Ajani, M. Karamouzis, Y. Janjigian, 2017 .